Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$78.20−0.48 (-0.61%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield 0.00%
Tarsus Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Tarsus Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was $74.16M. For fiscal 2025 it was -$12.45M. The highest annual figure on record is $3.75M in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.45M | – |
| FY2024 | Dec 31, 2024 | -$83.03M | – |
| FY2023 | Dec 31, 2023 | -$117.49M | – |
| FY2022 | Dec 31, 2022 | -$49.03M | -1408.2% |
| FY2021 | Dec 31, 2021 | $3.75M | – |
| FY2020 | Dec 31, 2020 | -$21.14M | – |
| FY2019 | Dec 31, 2019 | -$3.67M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $61.22M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.65M | – |
| Q4 FY2025 | Dec 31, 2025 | $19.33M | – |
| Q3 FY2025 | Sep 30, 2025 | $18.26M | – |
| Q2 FY2025 | Jun 30, 2025 | -$29.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$20.65M | – |
| Q4 FY2024 | Dec 31, 2024 | -$22.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.65M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.40M | – |
| Q1 FY2024 | Mar 31, 2024 | -$37.79M | – |
| Q4 FY2023 | Dec 31, 2023 | -$39.34M | – |
| Q3 FY2023 | Sep 30, 2023 | -$32.36M | – |
| Q2 FY2023 | Jun 30, 2023 | -$23.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$21.97M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$18.61M | -361.7% |
| Q2 FY2022 | Jun 30, 2022 | -$4.26M | -120.7% |
| Q1 FY2022 | Mar 31, 2022 | -$15.29M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.12M | – |
| Q3 FY2021 | Sep 30, 2021 | $7.11M | – |
| Q2 FY2021 | Jun 30, 2021 | $20.55M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.79M | – |
| Q4 FY2020 | Dec 31, 2020 | -$10.01M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.57M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.56M | – |
| Q1 FY2020 | Mar 31, 2020 | -$2.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$806.00K | – |
See a number that looks wrong?